Wu Xize, Pan Jiaxiang, Yu Jj Jiajia, Kang Jian, Hou Siyi, Cheng Meijia, Xu Lili, Gong Lihong, Li Yue
Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, China.
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, China.
J Ethnopharmacol. 2023 May 23;308:116289. doi: 10.1016/j.jep.2023.116289. Epub 2023 Feb 22.
DiDang Decoction (DDD) is a traditional classical prescription that has been used to treat atherosclerosis (AS) and hyperlipidemia (HLP) in China. Nevertheless, the underlying mechanism of DDD remains unclear.
To validate the mechanism of DDD in AS and HLP based on network pharmacology and in vitro experiments.
The chemical components of DDD were obtained from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) database and literature mining, and the disease targets of AS and HLP were obtained from the Gencards, OMIM, and DisGeNET databases. The intersection genes were imported into the STRING database to construct protein-protein interaction (PPI) network, and the DAVID database was used for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Combined with the results of KEGG pathway analysis, the HIF-1 signaling pathway was selected for further in vitro experiments.
The results showed that network pharmacology predicted 112 targets related to DDD treatment of AS and HLP, and the top 10 related pathways are: Lipid and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications, Chemical carcinogenesis - receptor activation, Pathways in cancer, Proteoglycans in cancer, Fluid shear stress and atherosclerosis, HIF-1 signaling pathway, Alcoholic liver disease, PPAR signaling pathway, and Coronavirus disease-COVID-19. In vitro experiments showed that DDD effectively reduced lipid accumulation in FFA-treated L02 cells; DDD attenuated mitochondrial damage and reduced ROS content; DDD inhibited ferroptosis and apoptosis; DDD up-regulated the expression of HIF-1α, Glutathione Peroxidase 4(GPX4), and Bcl2 proteins, and down-regulated expression of Bax protein.
DDD exerts therapeutic effects on AS and HLP through multiple targets and pathways, and improves mitochondrial function, reduces ROS content, inhibits ferroptosis and apoptosis by activating the HIF-1 signaling pathway, which provides reliable theoretical and experimental support for DDD treatment of AS and HLP.
抵当汤(DDD)是中国一种用于治疗动脉粥样硬化(AS)和高脂血症(HLP)的传统经典方剂。然而,DDD的潜在作用机制仍不清楚。
基于网络药理学和体外实验验证DDD治疗AS和HLP的作用机制。
从中药系统药理学数据库与分析平台(TCMSP)数据库及文献挖掘中获取DDD的化学成分,从Gencards、OMIM和DisGeNET数据库中获取AS和HLP的疾病靶点。将交集基因导入STRING数据库构建蛋白质-蛋白质相互作用(PPI)网络,并使用DAVID数据库进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。结合KEGG通路分析结果,选择HIF-1信号通路进行进一步的体外实验。
结果表明,网络药理学预测了112个与DDD治疗AS和HLP相关的靶点,前10个相关通路为:脂质与动脉粥样硬化、糖尿病并发症中的AGE-RAGE信号通路、化学致癌作用-受体激活、癌症中的通路、癌症中的蛋白聚糖、流体切应力与动脉粥样硬化、HIF-1信号通路、酒精性肝病、PPAR信号通路和冠状病毒病-COVID-19。体外实验表明,DDD可有效减少游离脂肪酸处理的L02细胞中的脂质积累;DDD减轻线粒体损伤并降低活性氧含量;DDD抑制铁死亡和细胞凋亡;DDD上调HIF-1α、谷胱甘肽过氧化物酶4(GPX4)和Bcl2蛋白的表达,并下调Bax蛋白的表达。
DDD通过多个靶点和通路对AS和HLP发挥治疗作用,并通过激活HIF-1信号通路改善线粒体功能、降低活性氧含量、抑制铁死亡和细胞凋亡,为DDD治疗AS和HLP提供了可靠的理论和实验依据。